z-logo
open-access-imgOpen Access
Altered Pharmacokinetics of Ceftazidime in Critically Ill Patients
Author(s) -
Carlos Maza Gómez,
J. J. Cordingly,
Mark Palazzo
Publication year - 1999
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.43.7.1798
Subject(s) - critically ill , pharmacokinetics , ceftazidime , medicine , intensive care medicine , critical illness , pharmacology , biology , pseudomonas aeruginosa , bacteria , genetics
Many critically ill patients have increased extracellular fluid which might affect ceftazidime pharmacokinetics. We investigated the pharmacokinetics of ceftazidime in 15 adult intensive care patients receiving 2 g of ceftazidime intravenously three times a day. The ceftazidime mean (standard deviation) apparent volume of distribution and terminal-phase half-life were 56.91 (25.93) liters and 4.75 (1.85) h, respectively, significantly greater than values reported previously for healthy controls (P < 0.001). The mean ceftazidime clearance and area under the curve at steady state were not significantly different from those previously reported for controls. We conclude that ceftazidime pharmacokinetics in critically ill patients were altered by an increased volume of drug distribution and elevated elimination half-life.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom